title: Sunitinib-induced thrombotic microangiopathy.
abstract: Sunitinib-induced thrombotic microangiopathy (TMA) is a secondary TMA caused by sunitinib. Despite the extensive use of sunitinib in patients with renal cell carcinoma and other malignancies, little is known about this complication of sunitinib. No clinical trials of sunitinib have studied this complication in any group of patients. We here review the normal physiology of vascular endothelial growth factor in the kidney, and discuss the pathogenesis, clinical and laboratory manifestations, pathological changes in the kidney, and the management of this uncommon complication of sunitinib.
authors.forename: Vanita
authors.initials: V
authors.lastname: Noronha
authors.forename: Sachin
authors.initials: S
authors.lastname: Punatar
authors.forename: Amit
authors.initials: A
authors.lastname: Joshi
authors.forename: Rushi V
authors.initials: RV
authors.lastname: Desphande
authors.affiliation: Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
authors.forename: Kumar
authors.initials: K
authors.lastname: Prabhash
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D007668:Kidney / Q000473:pathology; D011507:Proteinuria / Q000139:chemically induced / Q000473:pathology; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use; D000077210:Sunitinib; D057049:Thrombotic Microangiopathies / Q000139:chemically induced / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib